3. July 2024: Prof. Matthias Guckenberger and Prof. Panagiotis Balermpas
presented: Radiation-Oncology changing clinical trials from ASCO Annual Meeting 2024: Critical appraisal from Radiation Oncologists for Radiation Oncologists
Matthias Guckenberger, MD, is Chairman of the Department for Radiation Oncology, University Hospital Zurich (USZ), and Professor at the University of Zurich (UZH). Integration of advanced imaging and radiotherapy into multimodality treatment of lung cancer has been a major research focus, especially stereotactic body radiotherapy (SBRT) for early stage NSCLC and oligo-metastatic disease. Safety and efficacy was evaluated in prospective clinical trials, in large multi-institutional and national patterns of care analyses. Mathematical and imaging-based modeling of tumor and normal tissue response to radiotherapy has been another focus. Overall, his research has been published in >300 peer-reviewed articles.
Prof. Balermpas was born in Athens and studied medicine in the Goethe-University, Frankfurt am Main. He completed his doctoral thesis in the department of Oncology and his residency in the Department of Radiation Oncology of the Frankfurt University Hospital. He completed his habilitation and received the venia legendi for radiation oncology in 2016 and worked further as senior consultant and faculty member there until 2018. In 2018 he moved to Switzerland and to Zurich University Hospital to work as senior consultant for Radiation Oncology. He still works there as chief of service and is in lead of the study office and the radiation oncology satellite of the university hospital at Zurich-Airport. Prof. Balermpas is vice-chair of the SAKK-head and neck group and member of the EORTC, ESTRO, DEGRO and Swiss head and neck society. His main focus is head and neck and skin cancer. He has authored several publications and conducted and participated in guidelines, preclinical studies and clinical trials.
